Latest news with #TevogenBio
Yahoo
30-05-2025
- Business
- Yahoo
Tevogen Details its Artificial Intelligence Initiative, Tevogen.AI; Proprietary AI-Powered Immunotherapy with Microsoft and Databricks Partnerships
WARREN, N.J., May 30, 2025 (GLOBE NEWSWIRE) -- Tevogen ('Tevogen Bio Holdings Inc.' or 'Company') (Nasdaq: TVGN), today provided stockholders with a detailed overview of its artificial intelligence initiative, aims to integrate advanced machine learning and predictive modeling into Tevogen Bio's proprietary ExacTcell™ technology to significantly enhance its target identification and pre-clinical processes, thereby strengthening the Company's pipeline of innovative immunotherapies, accelerating clinical timelines, and substantially reducing development costs. currently has two proprietary technologies, each with patents pending, and an internal valuation of these assets is forthcoming. The Company plans to expand its AI initiative with applications that extend well beyond Tevogen Bio. In preparation for this anticipated growth, Tevogen is expanding its headquarters to include dedicated facilities for team of data scientists and engineers. Tevogen CEO, Dr. Ryan Saadi, commented, 'Healthcare is one of the largest segments of our economy, projected to approach $5 trillion in the U.S. in 2025 and a significant contributor to our rising national debt. vision extends beyond transforming how therapies are developed; it is expected to make a meaningful impact across multiple sectors of healthcare. I applaud the leadership team at and our strategic partners for their innovative efforts and contributions that will help define the future of healthcare.' Strategic Partnerships: Microsoft (Nasdaq: ): Provides industry-leading AI expertise, cloud computing infrastructure (Azure), and scientific resources to accelerate drug discovery processes. Databricks: Supplies specialized data engineering and analytics capabilities to refine Tevogen's AI models and enhance predictive accuracy. Proprietary Technology: PredicTcell™: AI tools capable of accurately predicting immunologically active peptide complexes and their interactions with T cell receptors, driving precision in immunotherapy treatments. The PredicTcell platform is a collection of multiple algorithms which performs in-silico predictions for candidate selection across multiple diseases. It continually improves with each accurate prediction through model tuning and reinforcement, helping expand our understanding of T cell receptor bindings, and therefore shortening the in-vivo process and expanding Tevogen Bio's pipeline. To date, has developed a continually expanding, terabyte-scale database that processes millions of protein and peptide interactions spanning numerous diseases and the human genome. AdapTcell™: Algorithms to decode the interactions between human leukocyte antigens (HLA) and T cells. AdapTcell is expected to significantly enhance Tevogen Bio's understanding of immune responses and open new therapeutic avenues, especially in areas with minimal existing data. As our understanding of key interactions expand, AdapTcell built algorithms perform experiments unlocking insights into genetics and proteomics. The platform aims to expand upon the cross sections of genetics and protein interactions and build an HLA specificity map. plans to expand into clinical trial patient identification using the information collected from its PredicTcell and AdapTcell platforms to drive efficiency, cost reduction and deliver targeted results. Tevogen remains committed to transparent communication with its stockholders and will continue providing clear updates on the progress and achievements of Forward Looking Statements This press release contains certain forward-looking statements, including without limitation statements relating to: Tevogen's plans for its research and manufacturing capabilities; expectations regarding future growth; expectations regarding the healthcare and biopharmaceutical industries; and Tevogen's development of, the potential benefits of, and patient access to its product candidates for the treatment of infectious diseases and cancer. Forward-looking statements can sometimes be identified by words such as 'may,' 'could,' 'would,' 'expect,' 'anticipate,' 'possible,' 'potential,' 'goal,' 'opportunity,' 'project,' 'believe,' 'future,' and similar words and expressions or their opposites. These statements are based on management's expectations, assumptions, estimates, projections and beliefs as of the date of this press release and are subject to a number of factors that involve known and unknown risks, delays, uncertainties and other factors not under the company's control that may cause actual results, performance or achievements of the company to be materially different from the results, performance or other expectations expressed or implied by these forward-looking statements. Factors that could cause actual results, performance, or achievements to differ from those expressed or implied by forward-looking statements include, but are not limited to: that Tevogen will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; changes in the markets in which Tevogen competes, including with respect to its competitive landscape, technology evolution, or regulatory changes; changes in domestic and global general economic conditions; the risk that Tevogen may not be able to execute its growth strategies or may experience difficulties in managing its growth and expanding operations; the risk that Tevogen may not be able to develop and maintain effective internal controls; the failure to achieve Tevogen's commercialization and development plans and identify and realize additional opportunities, which may be affected by, among other things, competition, the ability of Tevogen to grow and manage growth economically and hire and retain key employees; the risk that Tevogen may fail to keep pace with rapid technological developments to provide new and innovative products and services or make substantial investments in unsuccessful new products and services; risks related to the ability to develop, license or acquire new therapeutics; the risk of regulatory lawsuits or proceedings relating to Tevogen's business; uncertainties inherent in the execution, cost, and completion of preclinical studies and clinical trials; risks related to regulatory review, approval and commercial development; risks associated with intellectual property protection; Tevogen's limited operating history; and those factors discussed or incorporated by reference in Tevogen's Annual Report on Form 10-K. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Tevogen undertakes no obligation to update any forward-looking statements, except as required by applicable law. Contacts Tevogen Bio Communications T: 1 877 TEVOGEN, Ext 701 Communications@ in to access your portfolio
Yahoo
25-05-2025
- Business
- Yahoo
Tevogen Peports Plans to Increase the Target Population for TVGN 489
Tevogen Bio Holdings Inc. (NASDAQ:TVGN) revealed plans to broaden the scope of its TVGN 489 experimental medication to encompass patients 65 years of age and above. A laboratory technician researching a sample of cells in a biotechnology laboratory. The action expands upon the company's October 2024 revenue forecast of around $1 billion in sales during the first year, with five-year projections ranging from $18 billion to $22 billion. The expanded market will be reflected in an updated risk-adjusted net present value. Sadiq Khan, MBA, Chief Commercial Officer, stated that the strategic choice coincides with a spike in instances of the highly contagious COVID variant NB.1.8.1, which was initially identified in China. Tevogen Bio Holdings Inc. (NASDAQ:TVGN) is increasing clinical production to satisfy consumer demand. TVGN 489 targets SARS-CoV-2 infections in immunocompromised patients, such as those with psoriatic arthritis, rheumatoid arthritis, B-cell tumors, and other malignancies. It was created utilizing Tevogen Bio Holdings Inc. (NASDAQ:TVGN)'s ExacTcell™ platform. It covers Long COVID as well. Since seniors (65 and above) were not taken into consideration in earlier forecasts, their inclusion in the specialty care pipeline significantly boosts commercial potential. While we acknowledge the potential of TVGN to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than TVGN and that has 100x upside potential, check out our report about this READ NEXT: and . Sign in to access your portfolio
Business Insider
24-05-2025
- Business
- Business Insider
Tevogen announces planned expansion of TVGN 489's target population
Tevogen (TVGN) announced a planned expansion of TVGN 489's target population to include patients 65 and older. Tevogen Bio's Chief Commercial Officer, Sadiq Khan, MBA, commented, 'As the U.S. begins reporting cases of the new COVID variant NB.1.8.1, previously identified in China, which is believed to be more contagious, we have prioritized expansion of clinical manufacturing capacity to addressing significant unmet medical needs.' Confident Investing Starts Here:
Associated Press
21-02-2025
- Business
- Associated Press
Tevogen Bio's First Trading Year Efficiency: 600% Higher Market Cap Per Team Member, 79% Insider-Owned
600% higher market cap per team member when compared to industry average. Source: Mr. Damodaran at the Stern School of Business at NYU. Current ownership breakdown: Insiders 79%; Independent Board Members 1%; Lead Investor 7%; SPAC Sponsor 6%; Others 8%. Assets believed to be valued in the billions. (Not reflected on Tevogen's balance sheet as internally developed intangible assets are generally not permitted to be capitalized as per US GAAP). Additional business updates to follow in coming days. WARREN, N.J., Feb. 21, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio ('Tevogen Bio Holdings Inc.' or 'Company') (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech company, aims to set new efficiency standards in the industry, to prove that innovation and cost-effectiveness can coexist. Built with the rising cost of drug development in mind, Tevogen's model aligns with current drug price reform efforts while challenging traditional biotech financing norms to ensure long-term sustainability. 'In today's rapidly changing biotech landscape, efficiency is not just a competitive advantage, it's a necessity. Rising drug costs and shifting market dynamics demand a new approach, and Tevogen Bio is proving that groundbreaking innovation may be achieved without excessive spending,' commented Ryan Saadi, MD, MPH, Founder and CEO of Tevogen Bio. About Tevogen Bio Tevogen Bio is a clinical-stage specialty immunotherapy company harnessing one of nature's most powerful immunological weapons, CD8+ cytotoxic T lymphocytes, to develop off-the-shelf, genetically unmodified precision T cell therapies to treat infectious disease and cancers, aiming to address the significant unmet needs of large patient populations. Tevogen Bio leadership believes that sustainability and commercial success in the current era of healthcare rely on ensuring patient accessibility through advanced science and innovative business models. Tevogen Bio has reported positive safety data from its proof-of-concept clinical trial, and its key intellectual property assets are wholly owned by the company, not subject to any third-party licensing agreements. These assets include three granted patents, nine pending US and twelve ex-US pending patents, two of which are related to artificial intelligence. Tevogen Bio is driven by a team of highly experienced industry leaders and distinguished scientists with drug development and global product launch experience. Tevogen Bio's leadership believes that accessible personalized therapeutics are the next frontier of medicine, and that disruptive business models are required to sustain medical innovation. Forward Looking Statements This press release contains certain forward-looking statements, including without limitation statements relating to: expectations regarding the healthcare and biopharmaceutical industries; Tevogen's development of, the potential benefits of, and patient access to its product candidates for the treatment of infectious diseases and cancer; Tevogen's plans to expand its efforts in artificial intelligence; Tevogen's ability to develop additional product candidates; Tevogen's use of funds from the grant; and the potential receipt of additional future grants. Forward-looking statements can sometimes be identified by words such as 'may,' 'could,' 'would,' 'expect,' 'anticipate,' 'possible,' 'potential,' 'goal,' 'opportunity,' 'project,' 'believe,' 'future,' and similar words and expressions or their opposites. These statements are based on management's expectations, assumptions, estimates, projections and beliefs as of the date of this press release and are subject to a number of factors that involve known and unknown risks, delays, uncertainties and other factors not under the company's control that may cause actual results, performance or achievements of the company to be materially different from the results, performance or other expectations expressed or implied by these forward-looking statements. Factors that could cause actual results, performance, or achievements to differ from those expressed or implied by forward-looking statements include, but are not limited to: that Tevogen will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; the effect of the recent business combination with Semper Paratus Acquisition Corporation (the 'Business Combination') on Tevogen's business relationships, operating results, and business generally; the outcome of any legal proceedings that may be instituted against Tevogen; changes in the markets in which Tevogen competes, including with respect to its competitive landscape, technology evolution, or regulatory changes; changes in domestic and global general economic conditions; the risk that Tevogen may not be able to execute its growth strategies or may experience difficulties in managing its growth and expanding operations; the risk that Tevogen may not be able to develop and maintain effective internal controls; costs related to the Business Combination and the failure to realize anticipated benefits of the Business Combination; the failure to achieve Tevogen's commercialization and development plans and identify and realize additional opportunities, which may be affected by, among other things, competition, the ability of Tevogen to grow and manage growth economically and hire and retain key employees; the risk that Tevogen may fail to keep pace with rapid technological developments to provide new and innovative products and services or make substantial investments in unsuccessful new products and services; the ability to develop, license or acquire new therapeutics; that Tevogen will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; the risk of regulatory lawsuits or proceedings relating to Tevogen's business; uncertainties inherent in the execution, cost, and completion of preclinical studies and clinical trials; risks related to regulatory review, approval and commercial development; risks associated with intellectual property protection; Tevogen's limited operating history; and those factors discussed or incorporated by reference in Tevogen's Annual Report on Form 10-K and subsequent filings with the SEC. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Tevogen undertakes no obligation to update any forward-looking statements, except as required by applicable law. Contacts
Yahoo
07-02-2025
- Business
- Yahoo
Tevogen Bio Meets BARDA TechWatch Team, Highlighting ExacTcell™ Technology's Potential as a Scalable Medical Countermeasure
WARREN, N.J., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio ('Tevogen Bio Holdings Inc.' or 'Company') (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech company, met the Center for the Biomedical Advanced Research and Development Authority (BARDA) TechWatch team. The discussion focused on Tevogen Bio's affordable and scalable ExacTcell technology, the positive results of its proof-of-concept (POC) clinical trial for TVGN 489, the use of Artificial Intelligence in its process and future manufacturing capabilities. During the meeting, Tevogen Bio discussed ExacTcell's unique ability to rapidly adapt to emerging viral threats, positioning it as a potential countermeasure to safeguard public health. Tevogen Bio will follow up with key federal entities and continue to update stakeholders. VITAL Biotech Accelerator Program Department of Defense - Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense Antivirals and Antitoxins Branch within BARDA's Division of Chemical, Biological, Radiological, and Nuclear Medical Countermeasures About Tevogen Bio Tevogen Bio is a clinical-stage specialty immunotherapy company harnessing one of nature's most powerful immunological weapons, CD8+ cytotoxic T lymphocytes, to develop off-the-shelf, genetically unmodified precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders, aiming to address the significant unmet needs of large patient populations. Tevogen Bio Leadership believes that sustainability and commercial success in the current era of healthcare rely on ensuring patient accessibility through advanced science and innovative business models. Tevogen Bio has reported positive safety data from its proof-of-concept clinical trial, and its key intellectual property assets are wholly owned by the company, not subject to any third-party licensing agreements. These assets include three granted patents, nine pending US and twelve ex-US pending patents, two of which are related to artificial intelligence. Tevogen Bio is driven by a team of highly experienced industry leaders and distinguished scientists with drug development and global product launch experience. Tevogen Bio's leadership believes that accessible personalized therapeutics are the next frontier of medicine, and that disruptive business models are required to sustain medical innovation. Contacts Tevogen Bio CommunicationsT: 1 877 TEVOGEN, Ext 701 Communications@ A video accompanying this announcement is available at
